6
Views
0
CrossRef citations to date
0
Altmetric
Original Article

Epirubicin in Childhood Acute Lymphoblastic and Myeloid Leukemia in Relapse

, , , , &
Pages 203-208 | Received 07 Jul 1989, Published online: 01 Jul 2009

References

  • Arcamone F., Penco S., Vigevani A. Adriamycin: New chemical development and analogs. Cancer Chemotherapy Reports 1975; 6(2)123–129
  • Arcamone F., Penco S., Vigevani A., Redaelli S., Franchi G., Di Marco A., Casazza A. M., Dasdia T., Formelli F., Necco A., Soranzo C. Synthesis and antitumor properties of new glycosides of Daunomycinone and Adriamycinone. Journal of Medical Chemistry 1975; 18(7)703–707
  • Wittes R., Young L. W. Phase II study of 4′-Epidoxoru-bicin Communication at the Workshop on Anthracyclines Analogs. IVth Course in Hematology organized by Alberto and Antonietta Mattarelli Foundation, Milan, February 1–5, 1982
  • Torti M. F., Bristow M. M., Lum L. B., Carter S. K., Howes A. E., Aston D. A., Brown B. W., Hannigan J. F., Meyers F. J., Mitchell E. P., Billingham M. E. Cardiotoxicity of Epirubicin and Doxorubicin: assessment by endomyocardial biopsy. Cancer Research 1986; 46: 3722–27
  • Cersosimo R. J., Ki Hong W. Epirubicin: a review of the pharmacology, clinical activity and adverse effects of an adriamycin analogue. Journal of Clinical Oncology 1986; 4: 425–39
  • Bonfante V., Villani F., Bonadonna G. Toxic and therapeutic activity of 4′-Epidoxorubicin. Tumori 1982; 68: 105–111
  • Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
  • Chessells J. M. Acute leukemia in Children. Acute Leukemias. Clinical Haematology 1986; 15: 727–53
  • Rivera G. K., Buchanan G., Boyett J. M., Camitta B., Ochs J., Kalwinsky D., Amylon M., Vietti T. J., Crist W. M. Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse. New England Journal of Medicine 1986; 315: 273–78
  • Minow R. A., Benjamin R. S., Gottlieb J. A. Adriamycin (NSC-123127) cardiomyopathy — an overview with determination of risk factors. Cancer Chemotherapy Reports 1975; 6: 195–201

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.